Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3030MR)

This product GTTS-WQ3030MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3030MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13693MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ4713MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ867MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ2168MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ13193MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ12931MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ2967MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ11412MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW